#DBVT

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing DBV Technologies (NASDAQ:DBVT) announced €166.7 million of gross proceeds from the full exercise of ABSA Warrants and BS Warrants issued in its March 2025 financing, resulting in issuance of 59,657,507 new shares and 71,005,656 second pre-funded warrants.Proceeds, together with existing cash, are intended to fund working capital, preparation/submission of a potential BLA and launch readiness for VIASKIN Peanut in children 4–7 in the U.S., if approved. The company estimates these funds support operations for at least 12 months and sees no substantial doubt about going concern as of the press release date.

1 month ago

#DBVT DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

Trade Alerts, Wednesday December 17, 2025 – Crystal Equity Research

2 months ago

Small-cap stocks gapping up in trading, Wed Dec 17th - #YCBD #VNRX #HKIT #EDBL #ATPC #VYME #UDMY #SGML #RITR #NETD #KOD #ISPO #HYMC #DBVT #TWO - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years DBV Technologies (Nasdaq:DBVT) announced positive topline Phase 3 VITESSE results for the VIASKIN Peanut patch in children aged 4–7. The trial met its primary endpoint: 46.6% responder rate on active vs 14.8% on placebo (difference 31.8%; 95% CI 24.5–39.0%; lower bound >15%; p=1x10-17). VITESSE enrolled 654 children (438 active, 216 placebo). Safety was consistent with prior studies: no treatment-related serious adverse events, 0.5% treatment-related anaphylaxis (n=2), discontinuations 3.2% active vs 0.5% placebo, and compliance 96.2%. A U.S. BLA submission in H1 2026 is on track. Positive topline results accelerate exercise of warrants, now exercisable through Jan 15, 2026.

2 months ago

#DBVT DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

Leading Indicators, Wednesday December 3, 2025 – Crystal Equity Research

3 months ago

Small-cap stocks with strong volume gains, Wed Dec 3rd - #TROO #RR #QCLS #PHVS #MNTS #KITT #KALV #IRBT #HTOO #FRST #DBVT #CAPR #BCTX #ABTC #WDH #NLOP #DSX #CXM - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Leading Indicators, Tuesday December 2, 2025 – Crystal Equity Research

3 months ago

Small-cap stocks with strong volume declines, Tue Dec 2nd - #BGLC #CDLR #ABTC #EPOW #BLTE #HKIT #DBVT #NIVF #DOGZ #RYOJ #FTEL #SDH #GIBO #WOK #JAGX #SONN #YKDG - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years DBV Technologies (NASDAQ:DBVT) announced completion of the last patient visit in the VITESSE Phase 3 trial of the VIASKIN® Peanut patch in peanut-allergic children aged 4–7 years. The double-blind, placebo-controlled treatment phase is complete and the company remains on track to report topline data in Q4 2025.The 12-month study enrolled 654 subjects randomized 2:1 across 86 sites in the U.S., Canada, Europe, the UK, and Australia. DBV described VITESSE as the largest treatment intervention study in peanut allergy and thanked investigators, patients, and caregivers for participation.

4 months ago

#DBVT DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Nasdaq: DBVT) announced an at-the-market sale of ADSs on October 29, 2025, raising approximately $30 million gross through Artisan via Citizens Capital Markets.The transaction issues 2,142,860 ADSs (representing 10,714,300 ordinary shares), priced at $14.00 per ADS (subscription price €2.4063), and is expected to settle on October 31, 2025. New shares represent 6.34% of existing Euronext-listed shares and dilute existing holders by ~5.96%. Management estimates cash runway extended to end of Q4 2026; topline pediatric results and BLA timing reiterated for 4Q2025–1H/2H2026.

4 months ago

#DBVT DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

DBV Technologies Reports Third Quarter 2025 Financial Results Châtillon, France, October 28, 2025 DBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock

4 months ago

#DBVT DBV Technologies Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

Trade Alerts, Wednesday October 15, 2025 – Crystal Equity Research

4 months ago

Small-cap stocks with strong volume gains, Wed Oct 15th - #WATT #VERI #UROY #THH #SANA #RKDA #OMER #KOSS #INV #HOND #FLL #EDAP #DBVT #CBUS #BACQ #ATXS #TE #HLIO #HI #FF - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (NASDAQ:DBVT) announced an At-The-Market sale of 2,307,692 ADSs (representing 11,538,460 ordinary shares) for gross proceeds of approximately $30 million at an at-the-market price of $13.00 per ADS (each ADS = 5 ordinary shares). The issuance price equates to a subscription price of €2.2264 per ordinary share (FX $1.1678/€1) and reflects a 3.41% discount to the prior Euronext Paris close. Settlement is expected on October 8, 2025, with ADSs admitted on Nasdaq and the new ordinary shares on Euronext Paris. The new shares represent 8.42% of existing Euronext-listed shares and imply ≈7.77% dilution on completion. A Form S-3 registration statement has been declared effective.

5 months ago

#DBVT DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (NASDAQ:DBVT) has established a new At-The-Market (ATM) Program on Nasdaq, allowing the company to sell up to $150 million of American Depositary Shares (ADS). Each ADS represents five ordinary shares, with Citizens JMP Securities acting as sales agent.The proceeds will primarily fund activities related to the Biologics License Application (BLA) and potential launch of VIASKIN® Peanut patch for toddlers aged 1-3 years, along with advancing their VIASKIN platform development. The program could result in a maximum potential dilution of approximately 50% based on existing share capital, with sales limited to qualified investors in the pharmaceutical and biotechnology sectors.

6 months ago

#DBVT DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

DBV Technologies Releases Latest Financial Report: Food Allergy Treatment Progress Updates Inside Access DBV Technologies' latest financial performance and clinical progress in food allergy treatments. Comprehensive H1 2025 report now available. Get insights.

7 months ago

#DBVT DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (NASDAQ:DBVT) reported its Q2 and H1 2025 financial results, highlighting a challenging period with increased operating expenses and net losses. The company's operating expenses rose to $69.9 million for H1 2025, up from $65.0 million in H1 2024, primarily due to the COMFORT Toddlers safety study launch.Net loss increased to $69.0 million in H1 2025 from $60.5 million in H1 2024, with loss per share at $(0.58). Cash position strengthened to $103.2 million as of June 30, 2025, boosted by a March financing deal of up to $306.9 million, including $125.5 million received in April. The company expects current cash to fund operations into Q2 2026, though substantial going concern doubts remain.

7 months ago

#DBVT DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old DBV Technologies (NASDAQ:DBVT) has announced the screening of its first subject in the COMFORT Toddlers supplemental safety study for their Viaskin® Peanut patch 250 μg, targeting peanut-allergic children ages 1-3 years old.The Phase 3 double-blind, placebo-controlled study will enroll approximately 480 subjects across 80-90 study centers in the U.S., Canada, Australia, UK, and Europe. The study includes a 6-month initial phase followed by an optional 18-month open-label treatment phase. The first screening took place at the Respiratory Medicine Research Institute of Michigan, with additional sites in Minnesota and Ontario now activated.The data from this study will support a Biologics License Application (BLA) submission anticipated in 2H 2026 under the Accelerated Approval Pathway, complementing the previously completed Phase 3 EPITOPE study data.

8 months ago

#DBVT DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

DBV Technologies Secures Full Shareholder Support at Annual Meeting: Key Governance Updates Clinical-stage biopharma DBV Technologies receives unanimous approval for all proposed resolutions at annual meeting. See complete voting details.

9 months ago

#DBVT DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Most searched small-cap stocks, Wed Jun 4th - #PTON #STSS #VLRS #UUUU #UEC #TRMD #SPCB #SGMT #SEDG #RCAT #QUBT #OMCL #MULN #EVH #DDD #DBVT #BTCS #BORR #BMGL #FSM - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

DBV Technologies Reveals Special CEO Pay Package Ahead of Critical Shareholder Vote New filing details exceptional compensation package for DBV Technologies CEO pending June 11 shareholder approval. Access full governance report details.

9 months ago

#DBVT DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks gapping up in trading, Tue May 27th - #SATL #MBAV #LUNR #FBRX #EU #DBVT #DGLY #VTEX #MTAL #ETWO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

NewYork

@newyork.activitypub.awakari.com.ap.brid.gy

11 months ago

Original post on benzinga.com

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And G...

www.benzinga.com/general/market-summary/2...

#AIR […]

[Original post on benzinga.com]

0 0 0 0

DBV's VIASKIN Peanut Patch Shows Breakthrough 83.5% Success Rate in Toddler Study Three-year study reveals strong efficacy of VIASKIN peanut allergy patch in toddlers, with majority achieving high tolerance levels. Longer wear time correlates with better outcomes.

1 year ago

#DBVT DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

www.stocktitan.net/news/DBVT/dbv-technologi...

0 0 0 0